| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T120 |
0-104 |
Sentence |
denotes |
Similar to developing vaccines, drugs effective against other RNA viruses were also repurposed for CoVs. |
| T121 |
105-178 |
Sentence |
denotes |
Two major types of drugs being nucleoside analogues and immunomodulators. |
| T122 |
179-309 |
Sentence |
denotes |
So far, the most common therapies tried in patients with CoVs are ribavirin, lopinavir/ritonavir, IFN, or their combinations [74]. |
| T123 |
310-656 |
Sentence |
denotes |
Despite the antiviral activity observed with in vitro studies, the clinical effect was not consistent [75], in that ribavirin does not prolong the survival of SARS-CoV patients [74,76], while lopinavir/ritonavir plus ribavirin seemed to improve clinical outcomes for SARS patients [77], but the improvement was not confirmed in MERS-CoV patients. |
| T124 |
657-823 |
Sentence |
denotes |
IFNs showed effective at inducing antiviral activity against both SARS-CoV and MRES-CoV, but without significant improvement in the outcomes for the patients [78,79]. |
| T125 |
824-990 |
Sentence |
denotes |
In addition to the drug regimens used in patients, numerous drugs developed for the treatment of infection with CoVs were thoroughly discussed in the literature [57]. |
